---
title: "Aim Immunotech Announces Expiration And Preliminary Results Of Its Rights Offering For Aggregate Gross Proceeds Of $1.8 Million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277792201.md"
datetime: "2026-03-04T14:00:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277792201.md)
  - [en](https://longbridge.com/en/news/277792201.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277792201.md)
---

# Aim Immunotech Announces Expiration And Preliminary Results Of Its Rights Offering For Aggregate Gross Proceeds Of $1.8 Million

March 4 (Reuters) - AIM ImmunoTech Inc (AIM.A) : \* AIM IMMUNOTECH ANNOUNCES EXPIRATION AND PRELIMINARY RESULTS OF ITS RIGHTS OFFERING FOR AGGREGATE GROSS PROCEEDS OF $1.8 MILLION Source text: Further company coverage: (AIM.A)

### Related Stocks

- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [AIM.US](https://longbridge.com/en/quote/AIM.US.md)

## Related News & Research

- [FDA Rejection Sparks Questions On Replimune Drug Approval Path](https://longbridge.com/en/news/282577359.md)
- [BUZZ-Allogene tumbles on $175 mln stock offering after cancer therapy data](https://longbridge.com/en/news/282722450.md)
- [Arcutis Biotherapeutics Targets ZORYVE Expansion, Raises 2026 Outlook and Turns Cash-Flow Positive](https://longbridge.com/en/news/282775123.md)
- [Mesoblast Secures Exclusive CAR-MSC Technology License; Stock Up](https://longbridge.com/en/news/282790104.md)
- [Sana Announces Strategic Collaboration With Mayo Clinic For Developing Type-1 Diabetes Therapy SC451](https://longbridge.com/en/news/282645188.md)